Last reviewed · How we verify
NCT04030949
Are Rectal and Genital Chlamydia Trachomatis Infections in Women Related to Anal Sex, Autoinoculation / Contamination
trial testing No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants in Chlamydia Trachomatis Genital Infection in 600 participants. Status unknown.
31 August 2021
Quick facts
| Lead sponsor | Region Östergötland |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 27 August 2019 |
| Primary completion | 31 August 2021 |
| Estimated completion | 1 August 2022 |
| Sites | 2 locations across Sweden |
Drugs / interventions tested
- No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
Conditions studied
- Chlamydia Trachomatis Genital Infection — all drugs for Chlamydia Trachomatis Genital Infection →
- Chlamydia Trachomatis Infection of Anus and Rectum — all drugs for Chlamydia Trachomatis Infection of Anus and Rectum →
Sponsor
Region Östergötland
Who can join
18 and older, female only, with Chlamydia Trachomatis Genital Infection or Chlamydia Trachomatis Infection of Anus and Rectum. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chlamydia trachomatis is the most common cause of sexually transmitted bacterial infection in Sweden, an infection that is notifiable according to the Communicable Diseases Act and the Communicable Diseases Ordinance. Women account for 57 % of all cases detected since 1993. Recently published studies describe a high proportion of positive rectal chlamydia tests in women and in half of the cases there is no history of anal sex. In almost 20 % of cases, chlamydia has only been found rectally. Samples in these studies were self-collected and although the sensitivity of modern NAATs (Nucleic Acid Amplification Tests) is very high, there is even high risk of contamination of the sample due to the short anatomical distance between the vagina and the anus. Furthermore the vaginal sample has been taken prior to the rectal sample in the largest study from the Netherlands, something that further increases the risk of contamination of the rectal sample. There are experimental animal models which support the theory that chlamydia can be transferred along the gastrointestinal tract! This is a possible explanation for the occurrence of rectal chlamydia in women who have not had anal intercourse, but it is necessary to minimize the risk of contamination. The study will take part in three STD-clinics (2 counties) where two clinics are in the county of Östergötland (Norrköping and Linköping with totally 300 000 inhabitants) and one in the county of Jönköping (120 000 inhabitants). The risk of contamination of the rectal samples is minimized as the rectal sample is taken first and with the use of a pediatric proctoscope (a proctoscope that is designed to examine children) which is first inserted in the anus to allow sample collection from the rectal mucosa above the pectinate line, while avoiding contact of the collecting swab with the perineal skin. Then vaginal speculum examination is performed and samples are taken from endocervix and vagina for C.trachomatis N.gonorrhoeae and M.genitalium tests. Extra samples from the anus and the vagina will be collected and immediately frozen to minus 80 degrees to allow further testing with vPCR (viability Polymerase Chain Reaction). Positive chlamydia samples will be further analyzed with a high resolution method (Multi Locus Sequence Typing, or MLST and if necessary Multi-Locus Variable number tandem repeat Analysis or MLVA) to make the discrimination of various chlamydia types possible.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Controversies and evidence on Chlamydia testing and treatment in asymptomatic women and men who have sex with men: a narrative review.
Dukers-Muijrers NHTM, Evers YJ, Hoebe CJPA, Wolffs PFG, et al · · 2022 · cited 33× · PMID 35287617 · DOI 10.1186/s12879-022-07171-2
Verify or expand the search:
- PubMed search for NCT04030949
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Region Östergötland trials
Trials by the same sponsor.
- NCT06346535 — PrimeCog: Primary Care Cognitive Testing · recruiting
- NCT06276192 — Digital Physiotherapy Treatment for Patients With Subacromial Pain Compared to Usual Physiotherapy in Primary Care · NA · not yet recruiting
- NCT07159516 — Identifying Birth-Related PTSD: Cutoffs for the City Birth Trauma Scale · completed
- NCT06659822 — Responding to Elder Abuse in GERiAtric Care - Dementia · completed
- NCT05782582 — Chronic Coronary Syndrome in Swedish Primary Care · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04030949 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Region Östergötland
- Last refreshed: 3 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04030949.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing